摘要
Optimal therapeutic and diagnostic efficacy is essential for healthcare's global mission of advancing oncologic drug development.Accurate diagnosis and detection are crucial prerequisites for effective risk stratification and person-alized patient care in clinical oncology.A paradigm shift is emerging with the promise of multi-receptor-targeting compounds.While existing detection and staging methods have demonstrated some success,the traditional approach of monotherapy is being reevaluated to enhance therapeutic effectiveness.Het-erodimeric site-specific agents are a versatile solution by targeting two distinct biomarkers with a single theranostic agent.This review describes the inno-vation of dual-targeting compounds,examining their design strategies,thera-peutic implications,and the promising path they present for addressing complex diseases.
基金
NIH Research Evaluation and Commercilization Hub,Grant/Award Number:1U01HL152410
USVA Medical Research Service,Grant/Award Number:I01 BX00096409
National Institutes of Health,Grant/Award Numbers:R01CA269221,R01CA225837。
